Taysha Gene Therapies’ (TSHA) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a $6.00 price objective on the stock.

TSHA has been the subject of several other research reports. Canaccord Genuity Group cut their target price on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. Chardan Capital restated a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, August 13th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Taysha Gene Therapies currently has a consensus rating of “Buy” and an average price target of $6.38.

Taysha Gene Therapies Stock Up 2.7 %

TSHA opened at $2.27 on Tuesday. Taysha Gene Therapies has a fifty-two week low of $1.19 and a fifty-two week high of $4.32. The company has a market capitalization of $465.22 million, a P/E ratio of 3.60 and a beta of 0.44. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.22 and a quick ratio of 5.22. The firm’s fifty day moving average price is $1.98 and its two-hundred day moving average price is $2.39.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its earnings results on Monday, August 12th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. The business had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $3.62 million. Taysha Gene Therapies had a negative net margin of 888.18% and a negative return on equity of 168.91%. During the same quarter in the previous year, the firm posted ($0.38) earnings per share. On average, analysts anticipate that Taysha Gene Therapies will post -0.35 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Avoro Capital Advisors LLC lifted its position in Taysha Gene Therapies by 328.2% during the 1st quarter. Avoro Capital Advisors LLC now owns 18,650,000 shares of the company’s stock valued at $53,526,000 after purchasing an additional 14,294,445 shares during the period. StemPoint Capital LP bought a new stake in shares of Taysha Gene Therapies during the first quarter worth approximately $3,122,000. Bank of New York Mellon Corp acquired a new position in Taysha Gene Therapies in the second quarter valued at approximately $1,018,000. Los Angeles Capital Management LLC bought a new position in Taysha Gene Therapies in the third quarter valued at approximately $416,000. Finally, Rhumbline Advisers acquired a new stake in Taysha Gene Therapies during the 2nd quarter worth $413,000. 77.70% of the stock is currently owned by institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.